Cargando…
COVID-19-associated pulmonary aspergillosis in hemodialysis patients
BACKGROUND: Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) is a fatal complication in the general population. However, there are few reports on CAPA in patients undergoing hemodialysis (HD). METHODS: This retrospective observational cohort study was conducted at a sing...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807313/ https://www.ncbi.nlm.nih.gov/pubmed/35498890 http://dx.doi.org/10.1093/ckj/sfac027 |
_version_ | 1784643641550045184 |
---|---|
author | Yamaoka, Mai Banshodani, Masataka Muraoka, Shiro Tanaka, Kenta Kimura, Ayaka Tani, Hiroki Hashimoto, Shinji Shiraki, Nobuaki Shintaku, Sadanori Moriishi, Misaki Tsuchiya, Shinichiro Masaki, Takao Kawanishi, Hideki |
author_facet | Yamaoka, Mai Banshodani, Masataka Muraoka, Shiro Tanaka, Kenta Kimura, Ayaka Tani, Hiroki Hashimoto, Shinji Shiraki, Nobuaki Shintaku, Sadanori Moriishi, Misaki Tsuchiya, Shinichiro Masaki, Takao Kawanishi, Hideki |
author_sort | Yamaoka, Mai |
collection | PubMed |
description | BACKGROUND: Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) is a fatal complication in the general population. However, there are few reports on CAPA in patients undergoing hemodialysis (HD). METHODS: This retrospective observational cohort study was conducted at a single center between December 2020 and June 2021. We enrolled 21 HD patients with COVID-19 undergoing treatment and divided them into two groups, CAPA and non-CAPA (COVID-19 with and without pulmonary aspergillosis), and evaluated their characteristics, clinical outcomes and comorbidities. RESULTS: The log-rank test revealed that the 90-day survival rate after the initiation of treatment for COVID-19 was significantly lower in the CAPA (n = 6) than in the non-CAPA group (n = 15) (P = 0.0002), and the 90-day mortality rates were 66.6% and 0% in the CAPA and non-CAPA groups, respectively. In the CAPA group, four patients died due to respiratory failure (on Days 6 and 20), gastrointestinal bleeding (Day 8) and sepsis (Day 33); the reverse transcription-polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remained positive when they died. The remaining two patients survived and the negative conversion of RT-PCR for SARS-CoV-2 was confirmed on Days 10 and 15. The negative conversion of serum (1, 3)-β-d-glucan (BDG) was confirmed on Day 15 in one patient; the BDG remained positive on Day 64 in the other. CONCLUSIONS: CAPA is a fatal complication in HD patients and the general population. Therefore, clinicians should consider the possibility of testing for CAPA in patients undergoing HD. Mycological workups may be helpful for the early detection of CAPA. |
format | Online Article Text |
id | pubmed-8807313 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-88073132022-02-02 COVID-19-associated pulmonary aspergillosis in hemodialysis patients Yamaoka, Mai Banshodani, Masataka Muraoka, Shiro Tanaka, Kenta Kimura, Ayaka Tani, Hiroki Hashimoto, Shinji Shiraki, Nobuaki Shintaku, Sadanori Moriishi, Misaki Tsuchiya, Shinichiro Masaki, Takao Kawanishi, Hideki Clin Kidney J Original Article BACKGROUND: Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) is a fatal complication in the general population. However, there are few reports on CAPA in patients undergoing hemodialysis (HD). METHODS: This retrospective observational cohort study was conducted at a single center between December 2020 and June 2021. We enrolled 21 HD patients with COVID-19 undergoing treatment and divided them into two groups, CAPA and non-CAPA (COVID-19 with and without pulmonary aspergillosis), and evaluated their characteristics, clinical outcomes and comorbidities. RESULTS: The log-rank test revealed that the 90-day survival rate after the initiation of treatment for COVID-19 was significantly lower in the CAPA (n = 6) than in the non-CAPA group (n = 15) (P = 0.0002), and the 90-day mortality rates were 66.6% and 0% in the CAPA and non-CAPA groups, respectively. In the CAPA group, four patients died due to respiratory failure (on Days 6 and 20), gastrointestinal bleeding (Day 8) and sepsis (Day 33); the reverse transcription-polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remained positive when they died. The remaining two patients survived and the negative conversion of RT-PCR for SARS-CoV-2 was confirmed on Days 10 and 15. The negative conversion of serum (1, 3)-β-d-glucan (BDG) was confirmed on Day 15 in one patient; the BDG remained positive on Day 64 in the other. CONCLUSIONS: CAPA is a fatal complication in HD patients and the general population. Therefore, clinicians should consider the possibility of testing for CAPA in patients undergoing HD. Mycological workups may be helpful for the early detection of CAPA. Oxford University Press 2022-01-29 /pmc/articles/PMC8807313/ /pubmed/35498890 http://dx.doi.org/10.1093/ckj/sfac027 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the ERA. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Article Yamaoka, Mai Banshodani, Masataka Muraoka, Shiro Tanaka, Kenta Kimura, Ayaka Tani, Hiroki Hashimoto, Shinji Shiraki, Nobuaki Shintaku, Sadanori Moriishi, Misaki Tsuchiya, Shinichiro Masaki, Takao Kawanishi, Hideki COVID-19-associated pulmonary aspergillosis in hemodialysis patients |
title | COVID-19-associated pulmonary aspergillosis in hemodialysis patients |
title_full | COVID-19-associated pulmonary aspergillosis in hemodialysis patients |
title_fullStr | COVID-19-associated pulmonary aspergillosis in hemodialysis patients |
title_full_unstemmed | COVID-19-associated pulmonary aspergillosis in hemodialysis patients |
title_short | COVID-19-associated pulmonary aspergillosis in hemodialysis patients |
title_sort | covid-19-associated pulmonary aspergillosis in hemodialysis patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807313/ https://www.ncbi.nlm.nih.gov/pubmed/35498890 http://dx.doi.org/10.1093/ckj/sfac027 |
work_keys_str_mv | AT yamaokamai covid19associatedpulmonaryaspergillosisinhemodialysispatients AT banshodanimasataka covid19associatedpulmonaryaspergillosisinhemodialysispatients AT muraokashiro covid19associatedpulmonaryaspergillosisinhemodialysispatients AT tanakakenta covid19associatedpulmonaryaspergillosisinhemodialysispatients AT kimuraayaka covid19associatedpulmonaryaspergillosisinhemodialysispatients AT tanihiroki covid19associatedpulmonaryaspergillosisinhemodialysispatients AT hashimotoshinji covid19associatedpulmonaryaspergillosisinhemodialysispatients AT shirakinobuaki covid19associatedpulmonaryaspergillosisinhemodialysispatients AT shintakusadanori covid19associatedpulmonaryaspergillosisinhemodialysispatients AT moriishimisaki covid19associatedpulmonaryaspergillosisinhemodialysispatients AT tsuchiyashinichiro covid19associatedpulmonaryaspergillosisinhemodialysispatients AT masakitakao covid19associatedpulmonaryaspergillosisinhemodialysispatients AT kawanishihideki covid19associatedpulmonaryaspergillosisinhemodialysispatients |